✓ FDA Inspections (12) ✓ Clinical Trials (1) ○ SEC Filings ✓ Press (20) ✓ EMA GMP (3) ✓ MHRA GMP (5) ✓ HC GMP (47)

Quick Facts: Lonza

Signal Score
72.8/100 (as of 2026-11-12)
Quality Compliance
86.7/100 — Clean EMA record: 3 active GMP certificates (no deductions)
Headquarters
Basel, Switzerland
Modalities
AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation, Small Molecule API, High-Potency APIs, Oral Solid Dose
Active Programs
1 confirmed from ClinicalTrials.gov across 1 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Lonza

Largest CGT CDMO globally by program count.

Signal Score & Pillar Breakdown

Quality Compliance 86.7
Clean EMA record: 3 active GMP certificates (no deductions)
Clean MHRA record: 5 compliant GMP certificates (no deductions)
Sources: FDA Data Dashboard, EMA EudraGMDP, MHRA GMDP
Clean EMA record: 3 active GMP certificates (no deductions) · Clean MHRA record: 5 compliant GMP certificates (no deductions)
FDA Inspections12 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-09-29)
EMA GMP Certificates3 on record
MHRA GMP Certificates5 on record
Most Recent HC OutcomeCompliant · 2026-01-28
HC Attribution47 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Clean EMA record: 3 active GMP certificates (no deductions)
Clean MHRA record: 5 compliant GMP certificates (no deductions)
Operations 50.0
1 active programs across 1 sponsors
Modalities: Small Molecule API, Recombinant Protein, Monoclonal Antibody, Microbial Fermentation, Oral Solid Dose, AAV, ADC, mRNA, High-Potency APIs, Cell Therapy, Lentiviral
Source: ClinicalTrials.gov
1 active programs across 1 sponsors · Modalities: Small Molecule API, Recombinant Protein, Monoclonal Antibody, Microbial Fermentation, Oral Solid Dose, AAV, ADC, mRNA, High-Potency APIs, Cell Therapy, Lentiviral
Programs 1
Sponsors1
ModalitiesAAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation, Small Molecule API, High-Potency APIs, Oral Solid Dose
1 active programs across 1 sponsors
Modalities: Small Molecule API, Recombinant Protein, Monoclonal Antibody, Microbial Fermentation, Oral Solid Dose, AAV, ADC, mRNA, High-Potency APIs, Cell Therapy, Lentiviral
Source: ClinicalTrials.gov facility matching
NCT04809766 Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment... PHASE1 Terminated
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability 75.0
Publicly traded — financial transparency
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Publicly traded — financial transparency
Capacity 75.0
Multi-site operations (11 manufacturing sites)
Broad modality coverage (11 modalities)
Sites: Houston, TX, Walkersville, MD, Geleen, Netherlands, Portsmouth, NH, Visp, Switzerland, Stein, Switzerland, Slough, United Kingdom, Vacaville, CA, Basel, Switzerland, Porriño, Spain, Singapore
Source: company profiles (manufacturing sites, modality breadth)
11 manufacturing sites
Press Signals20 articles (not scored)
Multi-site operations (11 manufacturing sites)
Broad modality coverage (11 modalities)

Lonza FDA Inspection History

2025-09
2025-08
2024-07
2024-03
2023-09
2023-07
2023-03
2022-11
2022-10
2021-11
2021-10
2026-02
NAI VAI OAI
Date Site Type 483 citations posted Classification
2025-09-29
Lonza Manufacturing LLC
Vacaville, California Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2025-08-22
Lonza Tampa LLC
Tampa, Florida Facility-linked
Drug Quality Assurance Yes Voluntary Action Indicated (VAI)
2024-07-10
Lonza AG
Basel Town Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2024-03-07
Lonza Biologics, Inc.
Portsmouth, New Hampshire Company-level
Human Cellular, Tissue, and Gene Therapies Not posted Voluntary Action Indicated (VAI)
2023-09-29
Lonza Tampa LLC
Tampa, Florida Facility-linked
Drug Quality Assurance Yes Voluntary Action Indicated (VAI)
2023-07-21
Lonza Biologics, Inc.
Portsmouth, New Hampshire Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2023-03-28
Lonza AG
Visp Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2022-11-04
Lonza AG
Basel Town Company-level
Drug Quality Assurance Not posted No Action Indicated (NAI)
2022-10-13
Lonza Biologics Plc
Slough Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2021-11-05
Lonza Walkersville, Inc.
Walkersville, Maryland Company-level
Blood and Blood Products Yes Voluntary Action Indicated (VAI)
2021-10-01
Lonza Tampa LLC
Tampa, Florida Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2026-02-06
Lonza Biologics, Inc.
Portsmouth, New Hampshire Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
Source: FDA Data Dashboard · Retrieved Nov 21, 2026

Lonza FDA 483 Findings 16 observations · 2021-11-05 → 2025-08-22 ?

By subsystem

  • Documentation & Records 6 (37.5%)
  • Equipment & Facilities 5 (31.2%)
  • Laboratory Controls 2 (12.5%)
  • Process Validation 1 (6.2%)
  • Data Integrity 1 (6.2%)
  • CAPA 1 (6.2%)

By severity

  • 5 — Critical: 1
  • 4 — Serious: 1
  • 3 — Moderate: 3
  • 2 — Minor: 11
  • Repeat observations: 0

Most severe findings

  • Critical (5) Data Integrity 2025-08-22 21 CFR 211.68(b)
    Computer control of master formula records

    "Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel."

  • Serious (4) Process Validation 2021-11-05 21 CFR 820.75(a)
    Lack of or inadequate process validation

    "A process whose results cannot be fully verified by subsequent inspection and test has not been adequately validated according to established procedures."

  • Moderate (3) Laboratory Controls 2025-08-22 21 CFR 211.110(c)
    In-process materials characteristics testing

    "In-process materials are not tested for identity, strength, quality and purity and approved or rejected by the quality control unit during the production process and after storage for long periods."

Lonza EMA GMP Compliance 3 certificates

2025-04
2025-02
2022-12
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
NCF-01/2025-GAL Lonza Biologics Porrino S.L. Spain 2025-04-07 COMPLIANT
NL/H 25/2055564A Lonza Netherlands B.V. Netherlands 2025-02-20 COMPLIANT
NL/H 22/2044124B Lonza Netherlands B.V. Netherlands 2022-12-01 COMPLIANT
Source: EMA EudraGMDP · Retrieved Nov 21, 2026

Lonza MHRA GMP Compliance 5 certificates

2025-12
2025-12
2016-02
2014-04
2010-06
Compliant Non-Compliant
Certificate Site City / Postcode Inspection Date Status
UK MIA(IMP) 18606 Insp GMP/IMP 18606/11099-0019[I] LONZA BIOLOGICS PLC SLOUGH SL1 4DX 2025-12-08 COMPLIANT
UK MIA 18606 Insp GMP/IMP 18606/11099-0019[H] LONZA BIOLOGICS PLC SLOUGH SL1 4DX 2025-12-08 COMPLIANT
UK GMP 43108 Insp GMP 43108/9937079-0003[H] LONZA BIOLOGICS TUAS PTE LIMITED SG-637377 2016-02-22 COMPLIANT
UK GMP 18606 Insp GMP 18606/835874-0005[H] LONZA BIOLOGICS PLC WOKINGHAM RG41 5TU 2014-04-29 COMPLIANT
UK GMP 18601 Insp GMP 18601/11093-0002[H] LONZA BIOLOGICS 03801 2010-06-14 COMPLIANT
Source: MHRA GMDP Database · Retrieved Nov 21, 2026

Japan-accredited overseas site (PMDA)

sterile, biologics, cell and gene therapy (CGT), general (non-sterile) · 5 sites

  • Visp, Switzerland · Lonza AG Visp — sterile, biologics, general (non-sterile) · valid to Aug 30, 2031
  • Slough, United Kingdom · Lonza Biologics plc. — biologics · valid to Jul 19, 2031
  • Houston, United States · Lonza Houston Inc. — cell and gene therapy (CGT) · valid to Apr 15, 2030
  • Portsmouth, United States · Lonza Biologics Inc. — biologics · valid to Jun 21, 2031
  • Vacaville, United States · Lonza Manufacturing LLC — biologics · valid to Sep 30, 2029

PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)

Clinical Activity 1 studies

Source: ClinicalTrials.gov · Retrieved Nov 21, 2026

Hiring Activity 100+ open roles Beta

From public job postings on Lonza's careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
100+
open roles (the board lists only its ~100 newest)
63
in manufacturing, quality, PD/MSAT, engineering or regulatory (63%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 19, 2026: 11 new postings, 11 taken down.
What this may mean
  • There is an open site-leadership posting (Executive Director, Quality Site Head Stein, Stein, CH). Openings like this are routine and have many causes, such as a promotion, a reorganization or a new site.
  • 1 posting use start-up or expansion wording in the title. Read the posting before assuming a new facility; the wording is sometimes routine.
By function
Manufacturing & operations 17
Quality (QA / QC) 15
Process development & MSAT 17
Engineering & facilities 14
Commercial, BD & client projects 8
Other (finance, HR, IT, other) 29
By site
Visp, CH profile site
7 mfg/ops · 6 QA/QC · 5 PD/MSAT · 6 eng. · 9 other
33
Portsmouth NH, US profile site
3 mfg/ops · 2 QA/QC · 1 PD/MSAT · 3 eng. · 3 other
12
Hyderabad, IN
· 3 QA/QC · 7 other
10
Basel, CH profile site
1 mfg/ops · 1 PD/MSAT · 1 eng. · 6 other
9
Stein, CH profile site
2 mfg/ops · 2 PD/MSAT · 1 eng. · 3 other
8
Vacaville CA, US profile site
· 2 PD/MSAT · 1 eng. · 1 other
4
Bend OR, US
· 1 QA/QC · 1 eng. · 1 other
3
+ 12 more locations
Modality words in job titles
Small molecule / API1mRNA1Oligonucleotide1
Notable roles
Executive Director, Quality Site Head Stein Site leadership · Stein, CH
Senior Technology Transfer Lead, Product Lifecycle Start-up / expansion wording · Stein, CH
Associate Director, GE Automation, MES, Standards Senior operations / quality role · Visp, CH
Head of Global Supply Chain Transformation Senior operations / quality role · Basel, CH
Head of Procurement, Lonza Capability Center, LCC Senior operations / quality role · Hyderabad, IN
Latest postings
XMLNAME, Senior, Program Manager, Advanced Synthesis Commercial, BD & client projects · Visp, CH
Supply Chain Systems, Process Specialist Manufacturing & operations · Visp, CH
Senior Technology Transfer Lead, Product Lifecycle Process development & MSAT · Stein, CH
Senior Product Manager, QC Microbiology Future Technologies Quality (QA / QC) · Walkersville MD, US
Senior Process Expert Logistics Manufacturing & operations · Stein, CH
Manufacturing Specialist Manufacturing & operations · Visp, CH
MSAT Specialist Process development & MSAT · Stein, CH
Intern Supply Chain Management Manufacturing & operations · Visp, CH
Executive Director, Quality Site Head Stein Other (finance, HR, IT, other) · Stein, CH
Analyst, QC, Product Testing, Shift Quality (QA / QC) · Tuas Singapore, SG
Coverage: counted from Lonza's own careers board. The board publishes only its ~100 newest postings, so the real number of open roles is likely higher. Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source: lonza.wd3.myworkdayjobs.com · Checked Nov 20, 2026 · Tracking since Oct 26, 2026

Company Signals 20 articles

Company announcements, not verified evidence. They do not change any score.
regulatory 2026-10-21
Lonza launches enhanced DNA-to-IND offering, enabling IND readiness in as Little as six months for more complex biologics - Manufacturing Chemist
Lonza launches enhanced DNA-to-IND offering, enabling IND readiness in as Little as six months for more complex biologics  Manufacturing Chemist
general 2026-10-21
Lonza upgrades organic growth model and mid-term financial ambitions at capital Markets Day; Q3 2026 in line with expectations - Manufacturing Chemist
Lonza upgrades organic growth model and mid-term financial ambitions at capital Markets Day; Q3 2026 in line with expectations  Manufacturing Chemist
partnership 2026-10-20
Lonza and Onava collaborate to accelerate AI-native biologics discovery with GS Ori-Go Vectors - Manufacturing Chemist
Lonza and Onava collaborate to accelerate AI-native biologics discovery with GS Ori-Go Vectors  Manufacturing Chemist
general 2026-10-19
Lonza Group stock pre-market at EUR 648.80: CDMO before the Xetra open - ad-hoc-news.de
Lonza Group stock pre-market at EUR 648.80: CDMO before the Xetra open  ad-hoc-news.de
general 2026-10-15
Lonza expands dual-payload ADC technology offering through Qurient agreement - Manufacturing Chemist
Lonza expands dual-payload ADC technology offering through Qurient agreement  Manufacturing Chemist
regulatory 2026-10-15
Lonza upgrades growth ambitions to target higher margins after CDMO transformation - Indian Pharma Post
Lonza upgrades growth ambitions to target higher margins after CDMO transformation  Indian Pharma Post
general 2026-10-14
Lonza Sees Maturing Projects Driving Profitability Higher Over Medium Term - WSJ
Lonza Sees Maturing Projects Driving Profitability Higher Over Medium Term  WSJ
partnership 2026-10-12
Lonza and Asimov collaborate to advance in vivo lentiviral vector manufacturing - Manufacturing Chemist
Lonza and Asimov collaborate to advance in vivo lentiviral vector manufacturing  Manufacturing Chemist
general 2026-10-12
CPHI Milan 2026: Lonza Capsugel backs capsule-in-capsule tech for sensitive actives - Nutrition Insight
CPHI Milan 2026: Lonza Capsugel backs capsule-in-capsule tech for sensitive actives  Nutrition Insight
regulatory 2026-10-09
Lonza and Asimov forge strategic collaboration to advance lentiviral vector manufacturing - Indian Pharma Post
Lonza and Asimov forge strategic collaboration to advance lentiviral vector manufacturing  Indian Pharma Post
general 2026-10-06
Lonza advances aseptic spray drying for high-dose biologics - Manufacturing Chemist
Lonza advances aseptic spray drying for high-dose biologics  Manufacturing Chemist
general 2026-10-02
Lonza, Asimov Partner to Advance Scalable Lentiviral Vector Manufacturing - Contract Pharma
Lonza, Asimov Partner to Advance Scalable Lentiviral Vector Manufacturing  Contract Pharma
general 2026-05-06
STARLIMS Completes Acquisition Of MODA® Platform From Lonza To Expand End To End Digital Manufacturing And Quality Capabilities - BioPharma APAC
STARLIMS Completes Acquisition Of MODA® Platform From Lonza To Expand End To End Digital Manufacturing And Quality Capabilities  BioPharma APAC
general 2026-05-05
Lonza Group Stock (CH0013841017): Dividend Ex-Date Set for May 13, 2026 - AD HOC NEWS
Lonza Group Stock (CH0013841017): Dividend Ex-Date Set for May 13, 2026  AD HOC NEWS
general 2026-04-27
CDMO Injectable Drugs Market Set to Boom Rapidly by 2033 |Lonza Group, Thermo Fisher Scientific, Catalent, Inc. - openPR.com
CDMO Injectable Drugs Market Set to Boom Rapidly by 2033 |Lonza Group, Thermo Fisher Scientific, Catalent, Inc.  openPR.com
general 2026-04-22
Lonza Group AG stock (CH0013841017): Is biopharma contract manufacturing strong enough to unlock new - AD HOC NEWS
Lonza Group AG stock (CH0013841017): Is biopharma contract manufacturing strong enough to unlock new  AD HOC NEWS
general 2026-04-22
Lonza Group AG stock (CH0013841017): Is biopharma contract manufacturing now the real growth engine? - AD HOC NEWS
Lonza Group AG stock (CH0013841017): Is biopharma contract manufacturing now the real growth engine?  AD HOC NEWS
general 2026-04-22
Lonza Group AG stock (CH0013841017): Why biocontracting stability now outweighs cell therapy uncerta - AD HOC NEWS
Lonza Group AG stock (CH0013841017): Why biocontracting stability now outweighs cell therapy uncerta  AD HOC NEWS
general 2026-04-21
Lonza Group AG stock (CH0013841017): Is its biopharma contract model resilient enough for new growth - AD HOC NEWS
Lonza Group AG stock (CH0013841017): Is its biopharma contract model resilient enough for new growth  AD HOC NEWS
general 2026-04-21
Lonza Group AG stock (CH0013841017): Why biopharma contract manufacturing now matters more for U.S. - AD HOC NEWS
Lonza Group AG stock (CH0013841017): Why biopharma contract manufacturing now matters more for U.S.  AD HOC NEWS

Frequently Asked Questions About Lonza

How many FDA inspections does Lonza have on record?
CDMO Signal tracks 12 FDA inspections for Lonza, sourced from the FDA inspection database. See the full inspection history above.
Has Lonza received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Lonza.
Does Lonza hold EMA or MHRA GMP certificates?
CDMO Signal tracks 3 EMA and 5 MHRA GMP certificates for Lonza.
How many clinical programs is Lonza linked to?
Lonza is associated with 1 clinical trial in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Lonza's CDMO Signal Score?
Lonza has a Signal Score of 73/100, based on quality, operations, financial stability, and capacity data.
Evaluating Lonza for a manufacturing program?
Use the free AI matchmaker to compare Lonza against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Lentiviral CDMOs → Cell Therapy CDMOs → mRNA CDMOs → ADC CDMOs → Recombinant Protein CDMOs →

Similar CDMOs

AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 79.9
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
Catalent
Tampa, FL
Signal Score: 76.1
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 90.1
Biologics, mRNA, Small Molecule API, Oral Solid Dose, High-Potency APIs, Sterile Fill-Finish
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
Signal Score: 86.9
Biologics, ADC, Small Molecule API, High-Potency APIs, Oral Solid Dose
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 86.7
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein

Compare Lonza with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Lonza
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.